about
Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update.Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.Calibration of myocardial T2 and T1 against iron concentration.Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.Practical management of iron overload.Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadApproaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxSymptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort.A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadA randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.Monitoring and treatment of iron overload: state of the art and new approaches.Increased leucocyte apoptosis in transfused β-thalassaemia patients.On T2* magnetic resonance and cardiac ironOxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasOn myocardial siderosis and left ventricular dysfunction in hemochromatosis.The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonanceTreatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC studyConcepts and goals in the management of transfusional iron overload.Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay.Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.Optimizing iron chelation strategies in beta-thalassaemia major.Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.The development of hydroxypyridin-4-ones as orally active iron chelators.Cross-talk between available guidelines for the management of patients with beta-thalassemia major.The pathophysiology of transfusional iron overload.
P50
Q33166802-D68B01F7-A321-4653-89E6-C96D12215FC6Q33783224-2BD986A0-4497-4545-9648-01242DFBFFA4Q33801826-F2671E72-B5A8-42CB-A818-18EFE520223FQ34083003-B8BF8A5D-13D1-4808-B8AF-48223BFA7D52Q34091560-59AB7781-071B-4366-923B-42530936004BQ34188658-10042EA5-D2AF-4B42-A13A-CBBB440CA2A5Q34434629-4D767285-46D4-4AFD-AD8D-40A5823EF63EQ34451527-D4D4C1BE-21D0-4D8A-9D45-56DF2D522985Q34516223-48F9450C-3656-4F0A-9D08-3672EA693427Q34610046-A0AD2A07-EF2F-4621-90CF-889538E60E6AQ34750514-6D4CF3D3-671A-4ECE-882F-A0244F47A155Q35062875-BF300310-9FB5-44D3-B055-CE8A63B77FA6Q35206809-A9D3B11D-8521-4729-BE8B-105AE62EB55BQ35589756-53ED37C7-63BC-49E0-9C60-1C68C1C5C1F9Q35813192-D65D5E98-C09D-4414-BCDA-2A6B16C3EC87Q35987342-D91E9B2E-6F61-46F4-A1EC-484804B67AC9Q36078676-A92EF18A-ABDB-4038-BD02-964D5683EF26Q36104589-D01C895F-8D4D-4021-A4FF-ABBA9023F67CQ36136232-85BBE96C-93BE-4894-AE02-9C4B13635114Q36214874-630B515D-97F0-414A-8BCC-13571630EF69Q36343351-96D58BB0-C070-495E-9D3C-B4EAE177E84BQ36420736-ED5124FC-211A-4477-A9C4-A96131DC1E31Q36524624-7EDF2065-3765-402E-BBF1-FD8F374F3490Q36569047-3DE70DE9-FAD0-412A-B064-4B58CE1D7D4DQ36752732-1E933E28-C25B-4BE5-B054-0BDBD90F36EBQ36868160-C998C41F-921F-438C-91D5-FF686EF138BDQ36879780-C6EF97DC-EDFF-42ED-8F70-ED3889BD314BQ36891845-BEF8E01E-DB9F-4132-9863-366C99DF238CQ36967110-A789DEEC-76A7-4AF4-A1F7-E0929ABEFA15Q36985140-3DE23F5B-5F4B-4BA3-8EB0-B1A200568AC1Q37214539-A9B7B0B1-6FEA-4C55-870F-14F40EE446DCQ37416334-A6564A05-4818-40D1-B769-7C97CE31B8A4Q37650448-9DE7C8C4-5AEB-49D4-839B-90DC70766816Q37684218-4505E641-C5FD-4BD1-9951-37BB6A247BC0Q37762810-E07B97CE-44C6-4247-9EC6-1A9D1347375DQ37809338-2577B329-390A-401B-BB67-87C6637B7129Q37918009-8F07C5E4-6141-4A70-956C-C79DB6843250Q38037033-CEE1E48C-D64B-412E-808B-DC0A0ACDD7FFQ38088886-77D0442E-BB35-476D-8BE3-6231EAFE1840Q38234245-A06E4F88-559C-434D-B3C7-027E950DC63D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John B Porter
@nl
John B Porter
@sl
John B. Porter
@en
John B. Porter
@es
type
label
John B Porter
@nl
John B Porter
@sl
John B. Porter
@en
John B. Porter
@es
altLabel
John Porter
@en
prefLabel
John B Porter
@nl
John B Porter
@sl
John B. Porter
@en
John B. Porter
@es
P106
P1153
7403427269
P21
P31
P496
0000-0003-3000-9359